Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

A widespread approach to modern cancer therapy is to identify a single oncogenic driver gene and target its mutant protein product (e.g. EGFR inhibitor treatment in EGFR-mutant lung cancers). However, genetically-driven resistance to targeted therapy limits patient survival. Through genomic analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Blakely, Collin M., Watkins, Thomas B.K., Wu, Wei, Gini, Beatrice, Chabon, Jacob J., McCoach, Caroline E., McGranahan, Nicholas, Wilson, Gareth A., Birkbak, Nicolai J., Olivas, Victor R., Rotow, Julia, Maynard, Ashley, Wang, Victoria, Gubens, Matthew A., Banks, Kimberly C., Lanman, Richard B., Caulin, Aleah F., John, John St., Cordero, Anibal R., Giannikopoulos, Petros, Simmons, Andrew D., Mack, Philip C., Gandara, David R., Husain, Hatim, Doebele, Robert C., Riess, Jonathan W., Diehn, Maximilian, Swanton, Charles, Bivona, Trever G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709185/
https://www.ncbi.nlm.nih.gov/pubmed/29106415
http://dx.doi.org/10.1038/ng.3990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709185/
https://www.ncbi.nlm.nih.gov/pubmed/29106415
http://dx.doi.org/10.1038/ng.3990

Ejemplares similares